Actos Lawsuits Mounting; Yet FDA Approves Generic Version Of Diabetes Drug

Share Article

Actos lawsuits and warnings about the risk of bladder cancer associated with Actos endure, yet the FDA approves the first generic version of the drug, Bernstein Liebhard LLP reports.

Actos lawsuits and rising concerns about the link between Actos and bladder cancer did not deter the U.S. Food and Drug Administration (“FDA”) from approving the first generic version of the diabetes drug, Bernstein Liebhard LLP reports.* Manufactured by Takeda Pharmaceuticals, Actos (pioglitazone), is a popular medication used to treat type 2 diabetes. Notwithstanding numerous studies linking Actos to bladder cancer, on August 17, 2012, the FDA approved the first generic version of the drug. The generic version, pioglitazone, manufactured by Mylan Pharmaceuticals, gained FDA approval for 15 milligram, 30 mg and 45 mg tablets. Both the brand and generic forms will carry the same warnings, including a Boxed Warning to emphasize that pioglitazone may cause or worsen heart failure, and a warning that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer.

“Based on the wave of studies, recalls and warnings associated with Actos, we are troubled by the FDA’s decision to approve a generic form of this medication,” said Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs and defective medical devices. “Just last week, a study published in the Journal of the National Cancer Institute concluded that Actos users are two to three times more likely to develop bladder cancer compared to patients taking other classes of diabetes medications.” The Firm is currently offering free and confidential case reviews to individuals who took Actos and have been diagnosed with bladder cancer.

Bladder Cancer Subject Of Actos Lawsuits

Despite the FDA’s recent action, Actos lawsuits continue to move forward. On July 13, 2012, the Honorable Rebecca Doherty, who is overseeing the federal consolidated action, In re: Actos (Pioglitazone) Products Liability Litigation (“MDL No. 2299”), currently underway in the U.S. District Court for the Western District of Louisiana, issued an order setting out deadlines for the course of the Actos litigation.** According to the order, the first federal Actos bladder cancer lawsuit trial is scheduled to begin on November 3, 2014 with the second trial set for July 8, 2015. Plaintiffs involved in the Actos litigation allege that the drug caused them to develop bladder cancer and that the manufacturer failed to warn consumers about the risks associated with Actos use.    

Those who developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the Actos litigation by visiting our website, For more information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website